Hoshine Silicon Industry And Two Other Growth Stocks With High Insider Ownership On Chinese Exchange

Amidst a backdrop of fluctuating economic indicators and a cooling property sector, China's market presents a complex landscape for investors. In such an environment, growth companies with high insider ownership, like Hoshine Silicon Industry, can offer unique stability and potential due to the alignment of management’s interests with shareholder values.

Top 10 Growth Companies With High Insider Ownership In China

Name	Insider Ownership	Earnings Growth
Zhejiang Jolly PharmaceuticalLTD (SZSE:300181)	24%	22.3%
KEBODA TECHNOLOGY (SHSE:603786)	12.8%	25.1%
Suzhou Shijing Environmental TechnologyLtd (SZSE:301030)	22%	54.9%
Ningbo Deye Technology Group (SHSE:605117)	24.8%	28.5%
Cubic Sensor and InstrumentLtd (SHSE:688665)	10.1%	34.3%
Anhui Huaheng Biotechnology (SHSE:688639)	31.5%	28.4%
Sineng ElectricLtd (SZSE:300827)	36.5%	39.8%
Arctech Solar Holding (SHSE:688408)	38.6%	25.8%
Fujian Wanchen Biotechnology Group (SZSE:300972)	14.9%	75.9%
UTour Group (SZSE:002707)	24%	33.1%

Click here to see the full list of 366 stocks from our Fast Growing Chinese Companies With High Insider Ownership screener.

We'll examine a selection from our screener results.

Hoshine Silicon Industry (SHSE:603260)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Hoshine Silicon Industry Co., Ltd. operates in the production and sale of silicon-based materials both domestically and internationally, with a market capitalization of approximately CN¥55.30 billion.

Operations: The company generates its revenue from the production and sale of silicon-based materials across both domestic and international markets.

Insider Ownership: 32.6%

Earnings Growth Forecast: 31.7% p.a.

Hoshine Silicon Industry, despite recent removals from major indices, shows a robust growth trajectory with forecasted earnings increasing by 31.69% annually. However, its Q1 2023 financials reflect a downturn with net income and revenue dropping to CNY 527.84 million and CNY 5,415.87 million respectively from higher figures last year. The firm's Price-To-Earnings ratio stands at an attractive 26.4x compared to the broader Chinese market's 28.4x, although concerns about debt coverage and declining profit margins could pose challenges ahead.

• Click here and access our complete growth analysis report to understand the dynamics of Hoshine Silicon Industry.
• The valuation report we've compiled suggests that Hoshine Silicon Industry's current price could be inflated.

Suzhou Novosense Microelectronics (SHSE:688052)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Suzhou Novosense Microelectronics Co., Ltd. is a company that specializes in the development and manufacturing of integrated circuits and sensors, with a market capitalization of approximately CN¥14.85 billion.

Operations: The company generates its revenue from the development and manufacturing of integrated circuits and sensors.

Insider Ownership: 25.1%

Earnings Growth Forecast: 109.5% p.a.

Suzhou Novosense Microelectronics, a key player in the automotive microelectronics sector, is anticipated to transition into profitability within three years, with earnings expected to surge by 109.5% annually. Despite a highly volatile share price and a recent substantial net loss of CNY 150.03 million in Q1 2024, the company's revenue growth is projected at 34% per year, outpacing the Chinese market average. Recent product launches in advanced automotive systems underscore its innovative edge but return on equity remains low at 2.4%.

• Take a closer look at Suzhou Novosense Microelectronics' potential here in our earnings growth report.
• According our valuation report, there's an indication that Suzhou Novosense Microelectronics' share price might be on the expensive side.

Intco Medical Technology (SZSE:300677)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Intco Medical Technology Co., Ltd. is a company based in China that specializes in the R&D, production, and marketing of medical consumables and equipment, with a market capitalization of approximately CN¥16.49 billion.

Operations: The company generates revenue from the production and sale of medical consumables, health care equipment, and physiotherapy care products.

Insider Ownership: 36%

Earnings Growth Forecast: 33% p.a.

Intco Medical Technology has demonstrated a significant turnaround with first quarter sales reaching CNY 2.20 billion, up from CNY 1.57 billion year-over-year, and a shift to a net income of CNY 238.2 million from a previous net loss. Despite recent dividend cuts to CNY 0.08 per 10 shares, the company's revenue and earnings growth are outpacing market averages at rates of 22.6% and 33% respectively, supported by competitive pricing relative to industry peers.

• Navigate through the intricacies of Intco Medical Technology with our comprehensive analyst estimates report here.
• Insights from our recent valuation report point to the potential undervaluation of Intco Medical Technology shares in the market.

Summing It All Up

• Click through to start exploring the rest of the 363 Fast Growing Chinese Companies With High Insider Ownership now.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com